Search results for "antico"

showing 10 items of 736 documents

Sexual Dysfunction and Mood Stabilizers in Long-Term Stable Patients With Bipolar Disorder.

2020

Abstract Background In addition to factors intrinsic to bipolar disorder (BD), sexual functioning (SF) can be affected by extrinsic causes, such as psychotropic drugs. However, the effect of mood stabilizers on SF and quality of life (QoL) is an underexplored research area. Aim To analyze SF in BD outpatients in euthymia for at least 6 months treated only with mood stabilizers and the association between SF and QoL. Methods A multicenter cross-sectional study was conducted in 114 BD outpatients treated with (i) lithium alone (L group); (ii) anticonvulsants alone (valproate or lamotrigine; A group); (iii) lithium plus anticonvulsants (L+A group); or (iv) lithium plus benzodiazepines (L+B gro…

Bipolar DisorderUrologyEndocrinology Diabetes and MetabolismSexual arousalmedia_common.quotation_subject030232 urology & nephrologyOrgasmLamotrigine03 medical and health sciences0302 clinical medicineEndocrinologyQuality of lifeAntimanic AgentsMedicineHumansBipolar disordermedia_commonAged030219 obstetrics & reproductive medicinebusiness.industrymedicine.diseasePsychiatry and Mental healthSexual desireSexual dysfunctionMoodCross-Sectional StudiesReproductive MedicineQuality of LifeAnticonvulsantsFemalemedicine.symptombusinessClinical psychologymedicine.drugAntipsychotic AgentsThe journal of sexual medicine
researchProduct

Effects of heparin treatment on hemostatic abnormalities in obese non-insulin-dependent diabetic patients.

1997

This study was conducted to identify the mechanisms responsible for coagulative and fibrinolytic alterations and to study the effects of a short-term treatment with low-dose heparin on hemostatic abnormalities in obese non-insulin-dependent diabetes mellitus (NIDDM) patients. Four groups of age- and sex-matched patients were studied: (1) lean nondiabetic subjects (n = 30) with a body mass index (BMI) less than 25 kg/m2 (lean control subjects), (2) obese nondiabetic subjects (n = 30) with a BMI greater than 30 kg/m2 (obese control subjects), (3) lean NIDDM patients (n = 30), and (4) obese NIDDM patients (n = 30). All subjects were tested on the following parameters: fibrinogen, factor VII, p…

Blood GlucoseMalemedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentFibrinogenTissue plasminogen activatorBody Mass Indexchemistry.chemical_compoundEndocrinologyInternal medicineFibrinolysismedicineHumansInsulinObesityBlood CoagulationHemostasisFactor VIIbusiness.industryHeparinFibrinolysisnutritional and metabolic diseasesAnticoagulantsHeparinMiddle AgedLipidsBlood Coagulation FactorsEndocrinologychemistryDiabetes Mellitus Type 2HemostasisCase-Control StudiesFemalebusinessPlasminogen activatorBody mass indexmedicine.drugMetabolism: clinical and experimental
researchProduct

Haemostasis in chronic kidney disease

2013

The coagulation system has gained much interest again as new anticoagulatory substances have been introduced into clinical practice. Especially patients with renal failure are likely candidates for such a therapy as they often experience significant comorbidity including cardiovascular diseases that require anticoagulation. Patients with renal failure on new anticoagulants have experienced excessive bleeding which can be related to a changed pharmacokinetic profile of the compounds. However, the coagulation system itself, even without any interference with coagulation modifying drugs, is already profoundly changed during renal failure. Coagulation disorders with either episodes of severe bl…

Blood PlateletsExcessive Bleedingmedicine.medical_specialtymedicine.medical_treatmentHemorrhageThrombophiliaInternal medicinemedicineHumansRenal InsufficiencyRenal Insufficiency ChronicHemostatic functionBlood CoagulationCoagulation DisorderHemostasisTransplantationbusiness.industryAnticoagulantsThrombosisBlood Coagulation Disordersmedicine.diseaseThrombosisSurgeryOxidative StressCoagulationNephrologyAntibodies AntiphospholipidCardiologyEndothelium VascularHemodialysisbusinessKidney diseaseNephrology Dialysis Transplantation
researchProduct

Panniculitis due to potassium bromide.

1998

Potassium bromide again is well known to be surprisingly effective in patients with severe myoclonic epilepsy in infants (SME). Rare side effects on the skin reappeared, such as the febrile nodular panniculitis (Weber-Christian syndrome). In 1993 we described the first three cases of necrotizing panniculitis and introduced the term 'halogen panniculitis'. It is a systemic disease with crops of subcutaneous nodules, fever, elevated sedimentation rate, hepatosplenomegalia, and abdominal pain. Later severe necrosis of the skin and adipose tissue may happen with deep ulcerations. History and course of five cases, described in this paper, suggest either an allergy or toxic reason. Histologic pic…

BromidesMaleSystemic diseaseAbdominal painPathologymedicine.medical_specialtyAllergyNecrosisPanniculitisAdolescentPotassium CompoundsAdipose tissueInflammationSkin DiseasesDevelopmental NeuroscienceRecurrenceSkin UlcermedicineHumansChildRetrospective StudiesEpilepsybusiness.industryGeneral Medicinemedicine.diseaseChild PreschoolPediatrics Perinatology and Child HealthMyoclonic epilepsyAnticonvulsantsFemaleNeurology (clinical)medicine.symptomPanniculitisbusinessBraindevelopment
researchProduct

Le contentieux de la rupture abusive de relations d'affaires établies entre dans le champ d'application de la clause compromissoire stipulée dans le …

2012

International audience; (Civ. 1re, 8 juillet 2010, n° 09-67.013, D. 2010. 2884, obs. X. Delpech, note M. Audit et O. Cuperlier ; ibid. 2540, obs. Centre de droit de la concurrence Yves Serra ; ibid. 2933, obs. T. Clay ; Rev. crit. DIP 2010. 743, note D. Bureau et H. Muir Watt ; cette Revue 2011. 667, obs. P. Delebecque ; Rev. arb. 2010. 513, note R. Dupeyré)

CONCURRENCEArbitrage international[SHS.DROIT]Humanities and Social Sciences/LawRupture des relations commerciales[SHS.DROIT] Humanities and Social Sciences/LawDessaisissementPratique anticoncurrentielleARBITRAGELoi de policeJuridiction étatiqueClause compromissoire
researchProduct

Thrombosis, fracture, and percutaneous removal of a patent foramen ovale closure device 1 month after successful deployment

2010

Several different devices have been developed for the percutaneous closure of interatrial defects and patent foramen ovale. Although the implantation of these devices is both safe and effective, a number of complications, both in the early and the late follow-up, may occur. We describe a case of device fracture manifested early (1 month after implantation) with the formation of massive thrombosis on the right atrial disc. The patient was treated with anticoagulants and the device was percutaneously retrieved. Our images allowed early noninvasive therapy and emphasize the need for echocardiographic follow-up early after implantation. © 2010 Wiley-Liss, Inc.

Cardiac Catheterizationmedicine.medical_specialtyTime FactorsPercutaneousSeptal Occluder DeviceForamen Ovale PatentProsthesis DesignRight atrialmedicineHumansRadiology Nuclear Medicine and imagingDevice Removalbusiness.industryAnticoagulantsThrombosisGeneral MedicineMiddle Agedmedicine.diseaseThrombosisProsthesis FailureSurgeryRadiographyTreatment OutcomePatent foramen ovaleFemaleCardiology and Cardiovascular MedicinebusinessEchocardiography TransesophagealCatheterization and Cardiovascular Interventions
researchProduct

Management of Patients with Asymptomatic and Symptomatic Carotid Artery Disease: Update on Anti-Thrombotic Therapy

2019

AbstractThe most common causes of ischaemic stroke are represented by carotid artery atherosclerotic disease (CAAD) and atrial fibrillation. While oral anticoagulants substantially reduce the incidence of thromboembolic stroke (< 1%/year), the rate of ischaemic stroke and other cardiovascular disease events in patients with CAAD remains high, ranging from 8.4 to 18.1 events per 100 patient-years. Similar to any other atherosclerotic disease, anti-thrombotic therapies are proposed for CAAD to reduce stroke and other cardiovascular events. The 2017 European Society of Cardiology (ESC)/European Society for Vascular Surgery (ESVS) guidelines recommend for patients with asymptomatic CAAD ≥60%…

Carotid Artery DiseasesMaleRisk0301 basic medicinemedicine.medical_specialtyCardiologyHemorrhageThromboembolic stroke030204 cardiovascular system & hematologyAsymptomatic03 medical and health sciences0302 clinical medicineRivaroxabanCarotid artery diseaseInternal medicineIschaemic strokeMyocardial RevascularizationmedicineHumansAgedAspirinbusiness.industryIncidence (epidemiology)Atherosclerotic diseaseAnticoagulantsAtrial fibrillationHematologyMiddle AgedAtherosclerosismedicine.diseaseClopidogrelReview articleCarotid Arteries030104 developmental biology[SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologieCardiovascular Diseasesanti-platelet; anti-thrombotic therapy; anticoagulant; aspirin; carotid artery disease; rivaroxabanCardiologyFemale[SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologiemedicine.symptombusinessPlatelet Aggregation InhibitorsThrombosis and Haemostasis
researchProduct

Comparison of heparin to citrate as a catheter locking solution for non-tunneled central venous hemodialysis catheters in patients requiring renal re…

2014

Background The incidence of acute kidney injury (AKI) is estimated at 10 to 20% in patients admitted to intensive care units (ICU) and often requires renal replacement therapy (RRT). ICU mortality in AKI patients can exceed 50%. Venous catheters are the preferred vascular access method for AKI patients requiring RRT, but carry a risk of catheter thrombosis or infection. Catheter lock solutions are commonly used to prevent such complications. Heparin and citrate locks are both widely used for tunneled, long-term catheters, but few studies have compared citrate versus heparin for patients with short-term, non-tunneled catheters. We aim to compare citrate 4% catheter lock solution versus hepar…

Catheter Obstructionmedicine.medical_specialtyCatheterization Central VenousTime Factorsmedicine.medical_treatmentHemodialysis CatheterCatheter ObstructionMedicine (miscellaneous)urologic and male genital diseasesHospitals UniversityStudy ProtocolAcute renal failureClinical ProtocolsDouble-Blind MethodRenal DialysisCitrate lockIntensive careUpper Extremity Deep Vein ThrombosisProhibitinsmedicineCentral Venous CathetersHumansPharmacology (medical)Heparin lockRenal replacement therapyCitratesProspective StudiesContraindicationbusiness.industryHeparinAcute kidney injuryAnticoagulantsEquipment DesignAcute Kidney Injurymedicine.diseasefemale genital diseases and pregnancy complicationsSurgeryCatheterIntensive Care UnitsTreatment OutcomeResearch DesignHemodialysisHemodialysisFranceCritically ill patientbusinessCatheter lockTrials
researchProduct

Natural Course, Clinical Profile, and Treatment Strategies for Cerebral Cavernous Malformations

2022

A large body of evidence has suggested that the natural biology for symptomatic cerebral cavernous malformations (CCMs) is dynamic. These lesions exhibit a temporal clustering epiphenomenon and usually manifest with multispectral clinical patterns, the most relevant being hemorrhagic and seizurogenic events. Most patients with cerebral cavernous malformations are asymptomatic, and the lesions are detected as incidentalomas. However, association with the CCM3 gene, Zabramski type I and II lesions, and brainstem location have the propensity to increase the bleeding events. The rebleeding risk is 20%/year per lesion, which supports the need for surgical strategies for brainstem cavernous malfo…

CavernomaHemangioma Cavernous Central Nervous SystemSeizuresHumansAnticonvulsantsSurgeryNeurology (clinical)PresentationCourseRadiosurgeryBrain StemManagementWorld Neurosurgery
researchProduct

Loss of input from the mossy cells blocks maturation of newly generated granule cells.

2007

The objective of this work is to check whether the input from the mossy cells to the inner molecular layer is necessary for the integration and maturation of the newly generated granule cells of the dentate gyrus (DG) in mice, and if after status epilepticus the sprouting of the mossy fibers can substitute for this projection. Newly generated cells were labeled by administration of 5-bromo-deoxyuridine either before or after pilocarpine administration. The neuronal loss in the hippocampus after administration of pilocarpine combined with scopolamine and diazepam seemed restricted to the hilar mossy cells. The maturation of the granule cells was studied using immunohistochemistry for calreti…

Cell typeCell SurvivalCognitive NeuroscienceScopolamineConvulsantsNerve Tissue ProteinsMuscarinic Antagonistschemistry.chemical_compoundMiceS100 Calcium Binding Protein GStatus EpilepticusmedicineAnimalsCell ProliferationDiazepamEpilepsyNeuronal PlasticitybiologyChemistryDentate gyrusStem CellsGranule (cell biology)PilocarpineNuclear ProteinsCell DifferentiationImmunohistochemistryDNA-Binding Proteinsnervous systemBromodeoxyuridinePilocarpineCalbindin 2Dentate GyrusMossy Fibers HippocampalNerve Degenerationbiology.proteinAnticonvulsantsFemaleNeuNCalretininNeuroscienceBromodeoxyuridineBiomarkersSproutingmedicine.drugHippocampus
researchProduct